1. Introduction
===============

Diabetes mellitus is characterized by chronic hyperglycemia, which may be caused by defects in either insulin secretion by the pancreas or insulin action in target tissues like skeletal muscles. The World Health Organization (WHO) projects that by the year 2030, the global prevalence of diabetes mellitus will have increased to about 366 million people \[[@B001]\]. Therefore, in the fight against type 2 diabetes mellitus, which accounts for about 95% of global diabetic cases, various drugs like sulphonylureas, thiazolidinediones and *α*-enzyme inhibitors are being used in the management of diabetes \[[@B002]\]. Even though such drugs are clinically used, they are associated with side effects like weight gain, fluid retention in the body, liver toxicity and increased frequency of heart failure \[[@B003], [@B004]\]. Therefore, a need exists for extensive research to identify bioactive compounds from natural products that can be used in the management of diabetes with holistic effects and very minimal or no side effects.

For the above reasons, pharmaceutical research into anti-diabetic drugs has recently diverted to natural products for either complementary medicine or isolation of bioactive compounds that can be developed into standard drugs. Because botanicals are widely used across many countries, evaluating their anti-diabetic potentials and their toxicity is of paramount importance \[[@B005]\]. *Cassia abbreviata* (*C. abbreviata*), known in Setswana as Monepenepe \[[@B006]\], is a plant belonging to the family Caesalpiniaceae and is widely distributed across Southern Africa. The plant has a brown bark, yellowish compound leaves, and long, cylindrical, dark-brown hanging pods \[[@B007]\]. It is extensively used in traditional medicine for the management of diabetes and other diseases \[[@B008]\], and the plant extract was reported to inhibit *α*-glucosidase activity \[[@B009]\]. Although the plant is used for the management of diabetes, pharmacological findings supporting the safety of its use are lacking. Therefore, the present study was planned with an aim to establish the hypoglycemic effects of *C. abbreviata* in diabetic albino rats and its possible mechanism of action.

2. Materials and Methods
========================

All chemicals used were purchased from Sigma-Aldrich (USA). Glucose oxidase kits were purchased from Agappe Diagnostics (India). All chemicals and reagents used were of analytical grade. The stem bark of *C. abbreviata* was collected from Maitengwe village and was authenticated at the Department of Biological Sciences, University of Botswana. The bark was cut into small pieces, air-dried and ground to powder. The powder was soaked in 70% ethanol for 72 hours at 25ºC. The mixture was filtrated using Whatman 0.45-μm filter paper and concentrated in a rotary evaporator to obtain a crude ethanolic extract.

The study started with *in-vitro* studies. In the first experiment, we investigated the effect of different concentrations of an ethanol extract of *C. abbreviata* (ECA) on crude *α*-glucosidase from rat intestines according to the method described in Ref \[[@B010]\]. Studies of the enzyme kinetics were also conducted to determine the kinetic constants for and the types of inhibition employed by ECA. The effect of ECA on glucose uptake by muscle tissues was also investigated using the hemi-diaphragms of the rats according to the method proposed in Ref \[[@B011]\]. The amount of glucose absorbed per gram tissue was calculated as the difference between the initial and the final concentrations of glucose in the medium containing Tyrode's solution.

For the *in-vivo* studies based on the timeline in Fig. [1](#F001){ref-type="fig"}, male Sprague-Dawley (SD) albino rats with weights from 180 to 210 g were obtained from the University of Botswana's animal house. They were then housed in the animal house with a 12-h/12-h dark-light cycle and a temperature of 25 ± 2ºC. They were fed normal rodent pellets and distilled water *ad libitum*. Type 2 diabetes mellitus was induced by feeding the animals a high-fat diet for 14 days, followed by an intra-peritoneal injection of 35 mg/kg body weight (bw) of streptozotocin (Sigma Aldrich) dissolved in freshly prepared 0.1-M citrate buffer (pH 4.5). The diet was prepared by mixing pure white sugar, bovine body fat and powdered normal rat pellets in the ratio 10:16:17, respectively. Animals were closely monitored, and on the 3^rd^ day, blood was drawn from their tails after overnight fasting; their blood glucose levels were determined using a glucometer (Accu-Check Active). Rats with fasting blood glucose levels exceeding 125 mg/dL were considered diabetic and used for the experiment. The experimental protocol was approved by the Institutional Animal Ethics Committee (UB/ RES/ACUC/001).

Animals were randomly divided into five groups with five animals per group. Group 1 (normal control, NC) received only distilled water. Group 2 (diabetic control, DC) received only the vehicle (distilled water). Group 3 (Met-180) was a diabetic group which received 180 mg/kg bw of metformin (standard drug). Groups 4 (ECA-150) and 5 (ECA-300) received 150 and 300 mg/kg bw of ECA, respectively. Animals were dosed by using oral gavage for 21 days. Their fasting blood glucose levels and body weights were determined at seven-day intervals for 21 days. Oral glucose tolerance tests (OGTTs) were conducted at the beginning and towards the end of the experiment. The glucose levels of rats that had been fasted overnight were monitored at 30-minutes intervals for 3 hours after the animals had been fed a 2 g/kg bw glucose solution.

After the experimental period, animals were sacrificed under diethyl ether to collect the kidneys and the livers for biochemical analyses. The activity of hepatic hexokinase was determined spectrophotometrically at 340 nm in liver homogenates according to the method described in Ref \[[@B012]\], and the enzyme activity was expressed as μmoL/mg/min. Determination of the glucose-6-phosphatase (G6Pase) activity was based on a modified method at 700 nm \[[@B012]\] in a Shimadzu UV-Vis spectrophotometer, and the enzyme activity was expressed as μmoL of inorganic phosphate liberated/mg of protein/minute.

The data obtained were expressed as means ± standard errors of the means (SEMs). The significance of the differences in the means was analyzed using an analysis of variance (ANOVA) with Sigma plot version 11. The level of statistical significance was set as *P* \< 0.05.

3. Results
==========

The effect of ECA on *α*-glucosidase was investigated. As Fig. [2](#F002){ref-type="fig"} shows, ECA inhibited the activity of sucrase (*α*-glucosidase enzyme) in a dose-dependent manner and with an inhibitory concentration giving 50% inhibition (IC~50~) of 1.4 mg/mL. Fig. [3](#F003){ref-type="fig"} and Table [1](#T001){ref-type="table"} show the inhibition of *α*-glucosidase by ECA. The Michaelis constant (K~m~) value remained unchanged at 2.86 (mg/mL)^-1^ while the maximal velocity (V~max~) value was reduced from 16.7 mg/mL/s in the control sample (absence of ECA) to 10.1 mg/mL/s in the presence of ECA. The effect of ECA on the glucose uptake by the isolated hemi-diaphragms of the rats is shown in Fig. [4](#F004){ref-type="fig"}. Compared to the normal control, the uptake of glucose by the hemi-diaphragms was significantly (*P* \< 0.05) increased by insulin and ECA. However, no significant (*P* \< 0.05) difference was observed between the insulin dose and the ECA dose used.

Across all groups, prior to induction of diabetes, the highest blood glucose levels occurred at 30 minutes (Fig. [5](#F005){ref-type="fig"}) whereas after 21 days of diabetes and treatment, the highest glucose levels occurred mostly at 60 minutes (Fig. [5](#F005){ref-type="fig"}). Results show that the used doses of ECA had an effect on the OGTT curves. Glucose normalization was observed after 3 hours. Although the glucose levels were reduced after 3 hours, significant and quicker recovery was observed in the NC, ECA-150, ECA-300 and Met-180 groups. The DC and the ECA-50 groups showed slow recovery phases. Moreover, after 21 days of diabetes and treatment, the glucose levels in the DC and the ECA-300 groups remained abnormally high, even after 3 hours. The effects of ECA on the fasting blood glucose levels after 21 days of treatment in diabetic rats are presented in Fig. [6](#F006){ref-type="fig"}. Results show that ECA significantly reduced the glucose levels in Group 4 (ECA-150) and Group 5 (ECA-300) (*P* \< 0.05) as compared to the results in the DC group. Metformin also showed similar effects. No significant differences (*P* \< 0.05) were observed between the glucose levels of the metformin-treated rats, the ECA-150 treated rats, and the NC rats. The effect of ECA on body weight is presented in Table [2](#T002){ref-type="table"} and shows that the body weights increased significantly (*P* \< 0.05) for the rats in the NC, Met-180 and ECA-150 groups. However, the body weights decreased significantly (*P* \< 0.05) for the rats in the DC group. No significant weight increases were observed for the rats in the ECA-300 group.

Analyses of tissues from both the livers and the kidneys (Fig. [7](#F007){ref-type="fig"}) showed that the activities of G6Pase were significantly (*P* \< 0.05) elevated in the diabetic animals in comparison with the normal control animals. Interestingly, the metformin dose of 180 mg/kg bw and the ECA doses of 150 and 300 mg/kg bw were found to lower significantly (*P* \< 0.05) the activities of G6Pase in both kidney and liver tissues in comparison with the rats in the DC group. The study also found that the activities of hexokinase (Fig. [8](#F008){ref-type="fig"}) in liver homogenates were significantly (*P* \< 0.05) elevated in diabetic animals given a dose of 150 mg/kg bw extract, followed by a dose of 300 mg/kg bw when compared with the activity in the animals in the normal control group. The rats in the MET-180 and the DC groups had the lowest hexokinase activities.

4. Discussion
=============

The anti-diabetic properties of ECA were assessed by using both *in-vitro* and *in-vivo* experiments. The effect of ECA on *α*-glucosidase enzyme was investigated. Alpha-glucosidase is a family of enzymes found on the luminal surfaces of the small intestines where their main function is to breakdown disaccharides, like maltose and sucrose, into monosaccharides, mainly glucose monomers, for easy absorption into the blood stream \[[@B013]\]. ECA was found to inhibit the catalytic activity of sucrase, which is responsible for catalytic breakdown of sucrose into glucose in the small intestines. The extract inhibited the activity of sucrase in a dose-dependent manner, with an inhibitory concentration giving 50% inhibition (IC~50~) of 1.4 mg/mL. This possibly implies that ECA reduces the rate of absorption of glucose and the amount of glucose absorbed into the blood stream in a manner similar to the commercially available *α*-glucosidase' Acarbose \[[@B013], [@B014]\].

Based on the enzyme kinetics, we found the inhibition of the activity of sucrase (*α*-glucosidase enzyme) to be non-competitive, which means that the substrate and the inhibitor (ECA) bind at different sites on the enzyme \[[@B015]\]. The inhibitor may bind to either the free site of the enzyme or the enzyme-substrate complex and, hence, prevent the catalytic breakdown of sucrose into glucose. The non-competitive inhibition implies that the inhibition cannot be overcome by increasing the concentration of the substrate and, hence, is likely not be adversely affected by the concentration of the substrate, such as Acarbose, which is a competitive inhibitor \[[@B015]\].

ECA also significantly promoted the uptake of glucose by the rats' hemi-diaphragms. Estimating the glucose uptake by hemi-diaphragms is a method commonly used in pharmacological research to study the peripheral uptake of glucose by body tissues \[[@B013]\]. The increased uptake of glucose caused by ECA in the hemi-diaphragms implies that ECA promotes the uptake of glucose by muscle tissues in the body, hence helping to reduce glucose in the blood stream. This increased uptake may be due to enhanced insulin sensitivity or increased expression of GLUT4 in muscle tissues \[[@B016]\].

For *in-vivo* studies, we started with OGTTs in normal rats under different treatment regimens. Results showed that ECA had an effect on the OGTT curves and that the glucose level had returned to normal after 3 hours. However, more significant effects of ECA on the OGTT curves were observed in the ECA-150 and the ECA-300 groups than were observed in the ECA-50 group; hence, doses of 150 and 300 mg/kg bw were chosen for further studies. The normalization of the glucose levels may be due to inhibition of *α*-amylase and *α*-glucosidase, enhanced insulin sensitivity, or increased glucose uptake by muscle and adipose tissues \[[@B017], [@B018]\]. Long-term studies were assessed on the basis of fasting glucose levels in animals fed different concentrations of ECA for 21 days. The results indicated that ECA at a dose of 150 mg/kg bw significantly reduced the fasting glucose levels in diabetic rats, but that reduction was not significantly different (*P* \< 0.05) from the reduction observed for metformin at a dose of 180 mg/kg bw. Significant reductions in the glucose levels were observed in the ECA-300 group (*P* \< 0.05) when compared with the DC group. The reductions in the glucose levels in the ECA-300 group differed significantly from those for the ECA-150 group.

Significant (*P* \< 0.05) increases in body weights were observed in the NC, Met-180 and ECA-150 groups. Rats in the DC group experienced significant weight reductions. Metformin is a commercially available hypoglycemic drug that works by reducing hepatic glucose output by inhibiting the activity of G6Pase under fasting and diabetic conditions \[[@B019]\]. It also has minimal insulin sensitizing effects and inhibits hepatic lactate uptake, hence its ability to lower basal glucose production and possible fasting blood glucose levels \[[@B019]\].

The lower (150-mg/kg bw) dose of ECA worked more effectively than the higher (300-mg/kg bw) dose, hence, implying some form dose -- independent manner. ECA seems to differ from other medicinal plants, which were reported to work in a dose-dependent manner \[[@B011], [@B020]\]. A hypothesis is that this difference, though not documented, may be due to ECA containing a compound that inhibits the bioactive hypoglycemic compound with increasing concentrations of the extract. The ability of ECA to lower the fasting blood glucose level in experimental diabetes may be linked to the presence of bioactive compounds like polyphenols, anthocyanins, anthranoids, anthraquinones, and tannins, which have been isolated from stem bark \[[@B008], [@B021]\]. These polyphenols also have been reported to possess anti-oxidant properties \[[@B021]\], which could be implicated in the scavenging of the radicals produced by streptozotocin, hence repairing beta cells or preventing further damage to beta cells.

The enzymatic activities of hepatic hexokinase and G6Pase, which are involved in the glycolysis, gluconeogenesis, and glycogenolysis pathways \[[@B022]\], were also investigated. The use of glucose by the liver depends heavily on the activity of hexokinase, which catalyzes the first step in glycolysis \[[@B023]\], while hepatic glucose production is determined primarily by the activity of G6Pase, which catalyzes the final steps of both gluconeogenesis and glycogenolysis \[[@B024]\] mainly during fasting and diabetic conditions. Therefore, the net hepatic glucose flux is the balance between the rate of glucose phosphorylation catalyzed by hexokinase, the first step of hepatic glucose utilization, and the rate of glucose dephosphorylation catalyzed by glucose-6-phosphatase, the last step of hepatic glucose production \[[@B024]\]. Therefore, the study found that ECA, specifically ECA-150, significantly promoted the enzymatic activity of hexokinase and inhibited the activity of G6Pase in both liver and kidney tissues. These observations mean that ECA-150 accelerates the rate of glycolysis, hence clearing glucose in the blood stream, and limits the rates of gluconeogenesis and glycogenolysis, hence preventing excessive hepatic glucose output and possibly preventing muscle degeneration, which could possibly explain the observed body weight changes in the animals.

5. Conclusion
=============

We conclude that ECA normalized blood glucose levels in diabetic rats. This normalization may be due to non-competitive inhibition of *α*-glucosidase and to improved glucose uptake and utilization in muscle tissues. The increased activity of hepatic hexokinase and the decreased activity of G6Pase in both kidney and liver tissues may also contribute to the hypoglycemic potential of ECA.
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![Effect of ECA on glucose uptake by the hemi-diaphragms of the rats. Results are represented as means (n = 3) + SEMs, and ^\*^*P* \< 0.05 in comparison with the normal control.](2093-6966-v20-n01-045-g004){#F004}

![Effect of ECA on the results of the oral glucose tolerance tests (A) before induction of diabetes and (B) after 21 days of diabetes and various treatments. Results are represented as means ± SEMs.](2093-6966-v20-n01-045-g005){#F005}

![Effect of ECA on fasting blood glucose levels. Results are represented as means ± SEMs. (\*) and (†) indicate statistical significance (*P* \< 0.05) in comparison with the NC and the DC, respectively.](2093-6966-v20-n01-045-g006){#F006}

![Effects of ECA on the activity of G6Pase in liver and kidney samples. Results are represented as means ± SEMs. (\*) and (†) indicate statistical significance (*P* \< 0.05) in comparison with the NC and the DC, respectively.](2093-6966-v20-n01-045-g007){#F007}

![Effect of ECA on the activity of hexokinase in liver samples. Results are represented as means (n = 5) ± SEMs. (\*) and (†) indicate statistical significance (*P* \< 0.05) in comparison with the NC and the DC, respectively.](2093-6966-v20-n01-045-g008){#F008}

###### Kinetic constants determined from the Lineweaver-Burk plot

                                 K (mg/mL)^-1^   V~max~ (mg.mL^-1^·s^-1^)
  ------------------------------ --------------- --------------------------
  Control (without ECA)          2.86            16.7
  Experimental (0.5 mg/mL ECA)   2.86            10.1

ECA, extract of *Cassia abbreviata*.

###### Effect of ECA on the body weights of the rats in the experimental groups

  Group     Initial body weight (g)   Final body weight (g)   Change (%)
  --------- ------------------------- ----------------------- ------------
  NC        241.9 ± 0.7               263.4 ± 0.9             8.9
  DC        242.7 ± 1.4               233.8 ± 0.7             -3.7^\*^
  MET-180   260.0 ± 2.9               291.9 ± 8               12.3^\*,†^
  ECA-150   264.3 ± 1.3               287.9 ± 9.1             8.9^†^
  ECA-300   236.9 ± 8.3               237.4 ± 1.4             0.2^\*^

Results are represented as mean ± SEM. (\*) and (†) indicate statistical significance (*P* \< 0.05) in comparison with the NC and the DC, respectively. ECA, extract of *Cassia abbreviata*; NC, normal; DC, diabetic; MET, metformin; SEM, standard errors of the means.
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